Clinical trial
PROVIDENCE-1: Study of Rifalazil in Chlamydia Pneumoniae Seropositive Patients
NCT00251849 · ActivBiotics, Industry · Unknown status
Key facts
| NCT number | NCT00251849 |
|---|---|
| Title | PROVIDENCE-1: Study of Rifalazil in Chlamydia Pneumoniae Seropositive Patients |
| Official title | Prospective Evaluation of Rifalazil Effect On Vascular Symptoms of Intermittent Claudication and Other Endpoints in Chlamydia Seropositive Patients |
| Lead sponsor | ActivBiotics, Industry |
| Status | Unknown status |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Peripheral Vascular Diseases, Intermittent Claudication |
| Intervention type | Drug |
| Interventions | Rifalazil |
| Enrollment | 274 |
| Start date | Nov 1, 2005 |
| Completion | Dec 1, 2007 |
| First posted | Nov 11, 2005 |
| Last update posted | Aug 21, 2008 |
| Countries | Brazil, Russia, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: